CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 203 enrolled
Drug / intervention
Teneligliptin 20 mg +1 moredrug
Likely dose
Teneligliptin 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00998881
NCT00998881Phase 3Completed
CompareCT.gov

A Phase III, Double-blind, Placebo Controlled, Monotherapy Study of MP-513 in Japanese Patients With Type 2 Diabetes Mellitus - Confirmative Study

Tanabe Pharma Corporation·interventional·Posted Oct 21, 2009·Updated Jan 2, 2026

In Brief

A Phase 3 clinical trial evaluating Teneligliptin 20 mg and Placebo for Type 2 Diabetes Mellitus. Completed, enrolled 203 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in patients with type 2 Diabetes for 12 weeks administration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 21, 2009
Enrollment StartSep 1, 2009
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 16.7 years ago

Interventions

Teneligliptin 20 mgdrug

Placebodrug